UK News


NICE recommends Cabometyx (cabozantinib) for hepatocellular carcinoma

Cabometyx (cabozantinib) has been recommended by NICE for previously treated hepatocellular carcinoma (HCC) in adult patients. The CELESTIAL phase 3 trial has shown significant improvements in progression-free survival as well as overall survival when compared with a placebo group.

Ipsen UK gratefully received this recommendation from NICE for the use of its drug to treat advanced HCC, a type of primary liver cancer, in patients who have already been treated with sorafenib, with a Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.1. The phase 3 CELESTIAL trial had generally positive results which presumably influenced this recommendation, with the trial including a patient population who received cabozantinib in second- or third-line treatment with sorafenib.

The primary endpoint of this trial was overall survival, with the new drug providing a statistically significant improvement in this area, when compared to the placebo group. The median overall survival with cabozantinib was 10.2 months, while the placebo group only saw 8.0 months. Similarly, cabozantinib appeared to improve progression-free survival, with the median in this area being 5.2 months, while the placebo only had 1.9 months.

Vanessa Hebditch, director of communications and policy at the British Liver Trust, commented: “People living with the most common form of primary liver cancer, HCC, have a poor prognosis and there are very few treatments available. Often, the disease is diagnosed so late that palliative care is the only option. The nurses on the British Liver Trust’s helpline hear every day from patients who are completely devastated. They live with uncertainty, hopelessness, and often stigma and isolation due to the image of liver cancer. Treatments that buy extra time can not only positively impact those individuals but can also have a huge positive impact on families and the wider community, so today’s recommendation is an important step forward in the treatment of HCC.”

Professor Tim Meyer, professor of experimental cancer medicine at UCL Cancer Institute and honorary consultant in medical oncology at the Royal Free Hospital, added: “HCC is the third leading cause of cancer death worldwide and has one of the lowest five-year survivals of all cancers. For patients with advanced disease, treatment options remain limited, and outcomes are poor. Today’s recommendation by NICE will make cabozantinib available to such patients and provides an important addition to the therapeutic landscape for HCC. Cabozantinib has been proven to improve survival, slow disease progression and delay deterioration in symptoms when used as a second- or third-line treatment, and the decision to allow its use will be welcomed by doctors treating this challenging disease.”

thumbnail SolasCure partners with US Army for better wound care technology

SolasCure partners with US Army for better wound care technology

SolasCure, a biotechnology company that is dedicated to working towards filling the current market gap in debridement – the removal of necrotic tissue to encourage healing – and healing solutions for chronic wounds has announced a partnership with the US Army’s Institute of Surgical Research (USAISR).

thumbnail COMMUNIQUÉ

COMMUNIQUÉ

thumbnail Spinal cord stimulator with AI technology receives CE mark certification

Spinal cord stimulator with AI technology receives CE mark certification

The HFX iq, a personalised spinal cord stimulation (SCS) system developed by Nevro that leverages artificial intelligence technology to manage chronic pain, has received CE mark certification in Europe.

thumbnail Pharma Role

Pharma Role

Pharmarole.com

thumbnail Contents

Contents

Page 13 – improving the patient experience: insights from uganda, the uk and us

thumbnail Comment

Comment

Welcome to the final edition of 2024: Pharmafocus December.

thumbnail Pharma Role SalarySurvey

Pharma Role SalarySurvey

Salarysurvey.pharmarole.com

thumbnail Antibacterial peptides instrumental in efficiency against resistant bacteria

Antibacterial peptides instrumental in efficiency against resistant bacteria

Earlier in November, the Chalmers University of Technology in Sweden published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics.

thumbnail PharmaTimes

PharmaTimes

Msea.pharmatimes.com

thumbnail Cytomos raises £5m for scale-up process

Cytomos raises £5m for scale-up process

Biotech company Cytomos has announced this month that it has raised £5m to scale up the production of its unique cell analysis technology.

thumbnail Ozempic potentially dethroned by CagriSema, but weight loss still wins

Ozempic potentially dethroned by CagriSema, but weight loss still wins

Leading global healthcare company Novo Nordisk, who is a top contender for the industry's first $1trn valuation after the launch of its groundbreaking diabetes drug Ozempic in 2017, is set to introduce a promising new weight-loss treatment called CagriSema.

thumbnail Revolutionary Alzheimer’s diagnostic blood test launches in the UK

Revolutionary Alzheimer’s diagnostic blood test launches in the UK

Advance Tests, committed to enhancing diagnostic accessibility and advancing early disease detection, announced the exclusive UK launch of LucentAD complete.

thumbnail AdipoPharma secures funding for clinical trial into its insulin resistance compound

AdipoPharma secures funding for clinical trial into its insulin resistance compound

French biotech AdipoPharma has announced that it has secured funding for a clinical trial into its type 2 diabetes therapeutic, PATAS.

thumbnail GSK’s linerixibat shows positive phase 3 results for cholestatic pruritus in PBC

GSK’s linerixibat shows positive phase 3 results for cholestatic pruritus in PBC

Global biopharma company GSK has announced positive phase 3 results for its cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) treatment, linerixibat, which is currently being studied in the GLISTEN trial.

thumbnail Phase 2b results announced by Barinthus Biotherapeutics for HBV003 trial

Phase 2b results announced by Barinthus Biotherapeutics for HBV003 trial

UK-based Barinthus Biotherapeutics has announced data from its ongoing phase 2b HBV003 clinical trial, which was presented at the American Association for the Study of Liver Diseases (AASLD) Meeting 2024.

thumbnail Puma Biotechnology initiates phase 2 trial for breast cancer drug

Puma Biotechnology initiates phase 2 trial for breast cancer drug

Puma Biotechnology has announced the initiation of its alisertib in cancer (ALISCATM-Breast1) phase 2 trial of alisertib in combination with endocrine therapy. Based on the outcomes of the trial, the company anticipates to meet with the US Food and Drug Administration (FDA) regarding an approval pathway.

thumbnail Johnson & Johnson receives MHRA approval for BALVERSA

Johnson & Johnson receives MHRA approval for BALVERSA

BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of the most common type of bladder cancer, metastatic or unresectable urothelial carcinoma.

thumbnail MHRA greenlights adapted nuvaxovid JN.1 COVID-19 vaccine for ages 12 and up

MHRA greenlights adapted nuvaxovid JN.1 COVID-19 vaccine for ages 12 and up

Approval of an updated version of the Nuvaxovid COVID-19 vaccine, developed by Novavax, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), to target the omicron JN.1 COVID-19 subvariant.

thumbnail Theramex receives recommendation for YSELTY in Scotland

Theramex receives recommendation for YSELTY in Scotland

Theramex, a dedicated women’s health company, has announced that the Scottish Medicines Consortium (SMC) has recommended YSELTY (linzagolix) for the treatment of moderate or severe symptoms of uterine fibroids (UFs) in adult women of reproductive age.

thumbnail Aravax expands to Oxford Science Park, boosting UK pharmaceutical development

Aravax expands to Oxford Science Park, boosting UK pharmaceutical development

Aravax, a biotechnology company specialising in next-generation immunotherapies, has launched a UK subsidiary at the Oxford Science Park.